Trial Profile
ISTODAX for Intravenous Infusion 10mg Drug Use Results Survey - Relapsed or Refractory Peripheral T-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 05 Dec 2023 Status changed from recruiting to completed.
- 10 Oct 2022 Planned End Date changed from 17 Apr 2024 to 17 Apr 2023.
- 10 Oct 2022 Planned primary completion date changed from 17 Apr 2024 to 17 Apr 2023.